Spotlight on Immuno-Oncology in Melanoma

Slides:

Advertisements

Similar presentations

Upfront Combination Therapy vs Step-Up Approach for PAH:

Advertisements

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Evolving Paradigms in Recurrent/Metastatic SCCHN

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Why Gene Therapy for Hemophilia?

Treatment Algorithms in Melanoma: Past, Present, and Future

Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer

Advanced NSCLC Without Actionable Mutations

State of the Art in HCC: Immune Checkpoint Modulation

New Patient Journeys in Non-small cell lung cancer

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

Progression After Cancer Immunotherapy in Advanced NSCLC

Introduction to Checkpoint Inhibitors

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Optimizing the Treatment of Recurrent/Metastatic SCCHN

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

Optimizing Outcomes in the Management of GIST

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

Novel and Emerging Approaches to Treating CLL

The Evolving Role of Immunotherapy in NSCLC

Optimizing Management of Advanced Bladder Cancer

Basics of Immunotherapy Potential Therapeutic Targets.

Advanced Lung Cancers: What's on the Horizon?

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Advancing the Treatment of IBD With Biologics

When Is Biologic Therapy Appropriate for HS?

Evolving Concepts in the Management of Head and Neck Cancers

Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

The Road to Quality Improvement in HER2-Positive Breast Cancer

Advances in Gastrointestinal Cancers

Implications of Emerging Treatments for Beta-Thalassemia

Patient-Centered Management in BRAF-Positive Metastatic Melanoma

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

A Guideline-Based Approach to HCV Care

The Changing Field of Melanoma: Ipilimumab.

Are We Making Progress in the Management of Huntington Disease?

Optimizing Joint Health in Hemophilia

Challenges and Opportunities

Preparing for Checkpoint Inhibitors in Breast Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Adjuvant Therapy in Melanoma

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

From Adjuvant to Metastatic in Melanoma

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Taking a Closer Look at Recurrent/Metastatic SCCHN

Going Beyond EXTREME in Head and Neck Cancer

Moving Care Forward in Advanced Gastric Cancer

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

New Options for the Treatment of Hepatocellular Carcinoma

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Immune Checkpoint Inhibitors in Lung Cancer

Combining Immunotherapy and Chemotherapy in NSCLC

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Recent Developments in the Treatment of Advanced and Metastatic RCC

Updates in Best Practices in Non-Small Cell Lung Cancer

Presentation transcript:

Spotlight on Immuno-Oncology in Melanoma

Introduction

Emerging Agents Epacadostat

Emerging Agents (cont) Epacadostat

Emerging Agents OX40

Emerging Agents (cont) OX40 Antibody

Emerging Agents 4-1BB

Emerging Agents 4-1BB Antibody

Emerging Agents LAG-3

Practical Implications of These Emerging Agents

Pembrolizumab Survival Updates KEYNOTE-001

Pembrolizumab Survival Updates KEYNOTE-006

Notes on Stopping Therapy

Combination Nivolumab/Ipilimumab Survival Updates CheckMate-067

Upfront Treatment

Combination Nivolumab/Ipilimumab Survival Updates CheckMate-069

Are Some Patients Cured with Immunotherapy?

Treating Patients Who Had Autoimmune Disorders or Preexisting irAEs

Treating Patients Who Had Autoimmune Disorders or Preexisting irAEs (cont)

Treating Brain Metastases

Thoughts on Treating Brain Metastases

Sequencing Therapy

irAEs and Potential Treatment Benefit

Discontinuing Treatment Due to AEs

AEs and Treatment Benefit

Practical Applications

Patients With Wild-Type Disease That Progresses With Immunotherapy

A Look to the Future

Concluding Remarks

Abbreviations

Abbreviations (cont)